Which version of larotinib/larlotinib is the first release?

Larotrectinib/ Larotrectinib is a drug used to treat tumors caused by mutations in the neurotrophic receptor tyrosine kinase (NTRK) gene. In order to achieve the best therapeutic effect, patients should take medications strictly according to the doctor's instructions. Larotrectinib, also known as Vitrakvi, is an innovative drug developed by Loxo Oncology. Its first version is mainly in capsule dosage form and oral solution dosage form.

How larotrectinib treatment produces clinically meaningful responses in patients with TRK fusion cancers regardless of patient age or tumor type NTRK gene fusions are genomic alterations that result in constitutively activated chimeric TRK fusion proteins that act as oncogenic drivers to promote cell proliferation and survival in tumor cell lines. In the clinical trials that served as the basis for the approval, larotrectinib demonstrated clinical benefit in a number of unique tumor types, including lung, thyroid, melanoma, gastrointestinal stromal tumor, colon, and soft tissue sarcoma.

In the initial version, the capsule dosage form of larotrectinib is 100mg*56 capsules, while the oral solution dosage form is 20mg/ml. Both dosage forms have received priority review and accelerated approval globally and are available in multiple countries/regions. In China, the capsule form of larotrectinib was approved for marketing in April 2022, followed by the oral solution in June.

In terms of price, the price of the original version of larotrectinib is relatively high. The price of capsules and oral solutions sold domestically and abroad may be around tens of thousands of RMB. However, the emergence of foreign generic versions has provided patients with more choices, and the price of each box sold may be only a few thousand RMB. These generic drugs are relatively low in price, but their efficacy is equivalent to that of the original drugs, providing patients with more economical and affordable treatment options.